Pioneering the first dedicated therapeutic for HCM
GET NOTIFIED about upcoming clinical trials:
Development Timelinefor Perhexiline
About Heart Metabolics
Heart Metabolics Limited is pioneering a pharmaceutical therapy for hypertrophic cardiomyopathy.
HCM is an inherited heart condition in which the contracting mechanism of the heart cell is defective. This leads to deleterious heart muscle thickening and a situation in which the heart is unable to pump enough blood to the rest of the body. Although about 600,000 people in the US alone have a gene mutation that places them at risk for HCM, it often goes undiagnosed because many people with the disease have few if any symptoms and can lead normal lives with no significant problems. However, in about 20% of these people, the condition can cause symptoms which include shortness of breath with exercise, chest pain, or problems with the heart’s electrical system. Sometimes these symptoms may be severe or even fatal.